German Chancellor Olaf Scholz Lauds Merck's €300 Million Investment in New Darmstadt Research Center, Bolstering Germany as a Top Biopharmaceutical Hub

German Chancellor Olaf Scholz emphasizes significance for Germany as research location at cornerstone laying ceremony Research center to accelerate biop...

April 26, 2024 | Friday | News
Cidara Therapeutics Strikes $128 Million Deal to Divest rezafungin, Bolstering Focus on Cloudbreak Development

  Transaction provides company with an estimated approximately $128 million in cost savings, including approximately $67 million in clinical de...

April 25, 2024 | Thursday | News
EXO Biologics Raises EUR 16M for Exosome Therapy Development

    EXO Biologics, a clinical-stage biotech and a pioneer in developing exosome-based therapies, announces the successful securing of a t...

April 24, 2024 | Wednesday | News
SNIPR Biome Receives CARB-X Funding for CRISPR Medicine Trials

  SNIPR Biome ApS (“SNIPR”), the company pioneering the development of precision medicines using CRISPR technology for microbial gene the...

April 22, 2024 | Monday | News
Colossal Propels Ancient DNA Research, Investing $7.5M to Pioneer Climate Solutions and Biodiversity Preservation

Colossal, the world’s first de-extinction company, today announces progress on its ancient DNA agenda and a go-forward vision to enable critical new ...

April 15, 2024 | Monday | News
EnteroBiotix Completes £27 Million Funding Round to Advance Microbiome Therapeutics for Gut Disorders

EnteroBiotix Limited, a clinical-stage biotechnology company focussed on developing best-in-class full-spectrum microbiome therapeutics,  announced th...

April 04, 2024 | Thursday | News
Addex and Perceptive Launch Neurosterix with $63 Million to Accelerate Development of Allosteric Modulator Therapeutics for Neurological Disorders

  Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage biopharmaceutical company specializing in allosteric modulation-based drug development,...

April 03, 2024 | Wednesday | News
Samsung Ventures Backs BrickBio to Pave the Way for Next-Generation Therapies

Samsung Ventures, a key player in the life sciences sector, has made a strategic investment in BrickBio, Inc., a preclinical-stage biopharmaceutical compan...

March 19, 2024 | Tuesday | News
Sosei Heptares Strikes EUR 755 Million Deal with Boehringer Ingelheim to Develop Groundbreaking Schizophrenia Treatment

Single-target agreement focused on development of novel, small molecule agonists of GPR52 discovered by Sosei Heptares with the potential to simultaneous...

March 11, 2024 | Monday | News
Kenai Therapeutics Secures $82 Million Series A Funding to Advance Parkinson's Disease Treatment Trials

  – Proceeds will be used to complete clinical demonstration trials of the lead candidate drug RNDP-001 for the treatment of Parkinson's di...

March 11, 2024 | Monday | News
AstraZeneca plans £650 million investment in UK

AstraZeneca intends to invest £450 million to research, develop and manufacture vaccines in Speke, Liverpool, a facility which will be operationall...

March 07, 2024 | Thursday | News
Willow Biosciences Secures Second Strategic Investment from Kalsec

Willow Biosciences, a leading biotechnology company focused on revolutionizing industrial manufacturing of pure, consistent, and sustainable functional ing...

March 04, 2024 | Monday | News
FogPharma® Secures $145 Million in Series E Funding to Revolutionize Cancer Treatment with Pioneering Helicon™ Peptide Technology

FogPharma®, a clinical-stage biopharmaceutical company dedicated to delivering a new class of therapies that go beyond the limits of currently availabl...

March 04, 2024 | Monday | News
Curve Therapeutics Secures £40.5 Million Series A Funding Led by Pfizer Ventures to Propel Cancer Drug Discovery Efforts

Curve Therapeutics, a pioneering biotechnology firm, announced a significant £40.5 million Series A funding round, led by Pfizer Ventures and joined ...

February 28, 2024 | Wednesday | News

Survey Box

Poll of the Week

Which area of biopharmaceutical research excites you the most?

× Please select an option to participate in the poll.
Processing...
× You have successfully cast your vote.
 {{ optionDetail.option }}  {{ optionDetail.percentage }}%
 {{ optionDetail.percentage }}% Complete
More polls
Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

© 2024 Biopharma Boardroom. All Rights Reserved.

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close